Rosnilimab is under clinical development by AnaptysBio and currently in Phase I for Vitiligo. According to GlobalData, Phase I drugs for Vitiligo does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Rosnilimab LoA Report. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Rosnilimab overview

Rosnilimab (ANB-030) is under development for the treatment of graft versus host disease, vitiligo, ulcerative colitis and moderate-to-severe rheumatoid arthritis. It is administered by subcutaneous and intravenous route. The drug candidate acts by targeting PD-1 immune checkpoint. It is developed based on the somatic hypermutation (SHM) platform.
It was under development of alopecia areata and inflammatory diseases.

AnaptysBio overview

AnaptysBio is a clinical-stage biotechnology company that focuses on the development of antibody candidates for the treatment of atopic dermatitis, ovarian cancer, lung cancer, asthma, psoriasis, inflammation and other autoimmune indications. The company develops its product candidates through its proprietary antibody discovery technology platform that is based on somatic hypermutation (SHM). The company has various product candidates under development for the treatment of moderate-to-severe adult atopic dermatitis, asthma, generalized pustular psoriasis and palmo-plantar pustular psoriasis, and human autoimmune diseases. The company has partnership with GlaxoSmithKline and Bristol-Myers Squibb to develop its product candidates. AnaptysBio is headquartered in San Diego, California, the US.

For a complete picture of Rosnilimab’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.